New injection aims to shrink skin cancer tumors before removal
NCT ID NCT06422936
Summary
This study is testing an experimental drug called BO-112, which is injected directly into basal cell carcinoma skin cancer tumors. The goal is to see if the injection can shrink or eliminate the tumors before they are surgically removed, and to check how safe it is. The trial will involve about 60 adults with early-stage, operable skin cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universitaria de Navarra (CUN)
Madrid, 28027, Spain
-
Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
-
Hospital Clínic Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital de Basurto
Bilbao, 48013, Spain
-
Instituto Valenciano de Oncología (IVO)
Valencia, 46009, Spain
-
Kaplan Medical Center
Rehovot, 7661041, Israel
-
Rambam Medical Center
Haifa, Israel
-
Soroka Medical Center
Beersheba, Israel
Conditions
Explore the condition pages connected to this study.